TRP_1170x120_3-8-19

Value-based contracts provide promise and potential

Value-based contracts provide promise and potential

There has been significant focus and attention paid to the issue of drug prices in the last few years. As Adam Fein, president of Pembroke Consulting Inc. and chief executive officer of Drug Channels Institute, has said, “Drugs are 12% of the costs, but 90% of the ­conversation.” Fortunately, the spirited national conversation about drug

Preserving the impact of biopharmaceutical innovation

Preserving the impact of biopharmaceutical innovation

NEW YORK — Health care economists, health system leaders and policy makers have been talking seriously about measuring and paying for value in health care for more than a decade. Hospitals, clinics, pharmacies and practitioners across the country now are starting to move in that direction, incentivized since 2015 by Medicare’s adoption of alternative care

Biopharma innovation just part of health care equation

Biopharma innovation just part of health care equation

Today we’re seeing significant scientific breakthroughs that are revolutionizing the treatment of challenging conditions like cancers and both rare and chronic diseases. Advances that activate the immune system or retool genes with a single treatment to change the course of disease all signal that personalized medicine is here and continuing to evolve. These amazing and

Should patients with same condition bear different costs?

Should patients with same condition bear different costs?

Suppose two customers who are both diagnosed with rheumatoid arthritis approach your pharmacy counter. The first line of treatment for rheumatoid arthritis works effectively for the first customer, but it doesn’t work well in managing the second customer’s symptoms. The second customer’s doctor recommends another treatment that is more effective for her, yet it is

Health policy in 2017: Innovation, value and access

Health policy in 2017: Innovation, value and access

For the past two years, organizations in the private and public sectors have been working to develop tools to support value-based health care and evidence-based medical decision making. In 2017, these efforts will take on an even greater urgency, driven by the ongoing, accelerating progress of biopharmaceutical research and development. As more — and more

Health care stakeholders need to talk

Health care stakeholders need to talk

With the heated rhetoric about Obamacare on the presidential campaign trail, congressional hearings focused on drug costs and news reports about these debates, is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and appropriate treatments and encourage future innovation? We believe

Access to medications, adherence go hand in hand

Access to medications, adherence go hand in hand

If the lack of medication adherence were an easy problem to solve, then everyone would be taking their medicines as directed, there would be no need for iPhone apps or electronic pill bottle reminders, patient health outcomes would be improved, and overall health care costs would be lower because of reduced complications or ­hospitalizations. Yet

ACOs spearhead shift to value-based care

ACOs spearhead shift to value-based care

Recently, U.S. Health and Human Services (HHS) Secretary Sylvia Burwell announced a lofty goal of tying 50% of all traditional Medicare payments to alternative payment models, such as accountable care organizations (ACOs) or bundled payment arrangements, by the year 2018. In announcing these ambitious goals, Burwell stated, “Whether you are a patient, a provider, a